IR Pharma company logo
  • Company overview
  • Meet the team
  • Why we're different;
  • Technology - The drug development process at IRP; The Drug Evaluation Process; Model systems
  • Portfolio
  • Contact us

  • An outstanding combination
    of scientific insights and
    practical solutions

    Diary

    IR Pharma will have a presence
    at the following conferences.
    Contact us to arrange
    a meeting with one of the team.




    May 19-24, 2017
    American Thoracic Society
    Annual Conference.
    Washington DC, USA.


    September 9-13, 2017
    European Respiratory Society
    Congress.
    Milan, Italy.








    Contact us

    IR Pharma
    National Heart & Lung Institute
    1st floor,
    Sir Alexander Fleming Building,
    Imperial College,
    London SW7 2AZ.
    T: +44 (0)20-7594 8579
    E: info@irpharma.co.uk

    Meet the team



    Dr Mark A Birrell - director


    ball

    Dr Mark A Birrell is an internationally recognised expert in the field of respiratory pharmacology, with over two decades' experience in both academia and industry. He runs the research group based at the National Heart & Lung Institute (NHLI), Imperial College, London, as well as educating both undergraduate and MRes students at the college. Dr Birrell was awarded a BSc with honours in pharmacology by the University of London. He spent several years at Aventis Pharma and left the company in 2000 to study for a PhD at the National Heart & Lung Institute under the supervision of Professor Maria Belvisi and Professor Sir Magdi Yacoub. As well as publishing key papers in respected respiratory and pharmacology journals, Dr Birrell works as a reviewer for a number of such publications. He has presented at the American Thoracic Society and the British Pharmacology Society (BPS), and is a member of both the BPS and the British Association of Lung Research.




    Dr Trevor Langley - director


    ball

    Dr Trevor Langley has extensive experience of the life-science industry gained through a number of executive board positions. In 2002, he formed BioMedical Business Partners (BMBP), to expand the concept of applying commercial skills to the process of spinning out innovative technology. A number of successful companies have been created under BMBP's guidance, in partnership with some of the UK's leading universities. His early industrial experience, after completing a PhD and carrying out post-doctoral research in the USA, was gained at Whatman Biochemicals Ltd where he undertook a number of management positions before being appointed managing director. Subsequently, he set up Imperial Biotechnology Ltd with venture capital backing and finance from the City of London. After the sale of the company in 1989, he joined Huntingdon Life Sciences as marketing & sales director, a role he held until 1995.